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Background: Diabetes is one of the multifactorial disorders with genetics and environmental factors playing
important role in its cause. In diabetes, the defects in cellular metabolism results in increasing free radicals. These
radicals react with other vital cellular molecules which are responsible in diabetes side effects. Human glutathione
S-transferases (GST) are a family of enzymes that catalyses conjugation of electrophilic substances with glutathione.
In this research the deletion of two of the most important genes of this family; GSTT1 and GSTM1 genes was
investigated as the risk factor for diabetes mellitus type II and one of its most important complications; retinopathy.
Material and methods: In this study deletion of GSTT1 and GSTM1 genes in 57 diabetics’ patients with retinopathy
and 58 diabetic peoples without retinopathy was examined. DNA was extracted from peripheral blood and then
multiplex PCR was performed following agarose gel electrophoresis to detect GSTT1 and GSTM1 null genotypes.
Data were analyzed with SPSS v16 software.
Results: The results indicated that there was significant relationship between GSTM1 null genotype with
retinopathy side effect of diabetes type 2. While there was no significant relationship between GSTT1 null
genotypes with retinopathy in diabetes type 2.
Conclusion: Significant correlation between GSTM1 null genotype and retinopathy in this and other studies could
indicate this fact that impair cellular metabolism result in increase free radicals and oxidative pressure. Therefore,
GST null genotypes may result in decrease antioxidant capacity which causes side effects of diabetes. Considering
the performance of different classes of GST null genotypes additional studies are required to confirm this study.
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There are many genetics and environmental factors in-
volve in multifactorial diseases such as heart diseases,
diabetes, high blood pressure and cancer. Interaction of
these factors and inheritance pattern is complex. Unlike
monogenic disease the occurrence chance of these dis-
eases cannot be predicted, but we can predict the inci-
dence rate of the disease [1].
Type 2 diabetes mellitus (T2DM) is recognized as a
worldwide public health problem due to the high medical
and socioeconomic costs that result from complications
associated with the disease. In general, T2DM is the most
common metabolic and multifactorial disease in which
both genetic and environmental factors are involved [1-3].* Correspondence: sheikhha@yahoo.com
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distribution, and reproduction in any mediumDiabetes is the latest step of a chronic and accelerating
disorder which results from insulin resistance, decrease of
functional pancreatic β cells and increase of glucose level.
Approximately all of the T2DM patients are insulin resist-
ance. Despite of numerous studies on insulin resistance,
the main cause of it is still not known. It seems that post
translation modification and mutations in the genes lead
to defect in the cell signaling pathway which can result in
insulin resistance [4]. Several genes have been identified
that are involved in the cellular pathway of glucose metab-
olism and storage. Defects in these genes can lead to dia-
betes or diabetes background. Among these genes are:
Adiponectin [1,2], PTPN1 [4], GLUT4,2 [5,6], PAX4 [7],
HNF1B [8] and PPARG [9]. People with T2DM are at risk
for several complications, including damage to the vascu-
lar system that leads to increase mortality [10]. Many side
effect of T2DM are cardiovascular disease, nephropathy,ntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of the most severe complications that can cause blindness
in patients. Blindness in diabetic patients is 25 times
higher than non-diabetics [11]. These complications could
be due to the cellular metabolism leading to hypergly-
cemia and to the production of free radicals which com-
bined with vital molecules result in various diseases.
The human glutathione S-transferases (GSTs) are a
family of enzymes known to act in the body as the
defense systems for neutralize free radicals. They play an
important role in the detoxification of electrophiles by
glutathione conjugation. For example, the function of
the GST enzymes has traditionally been considered to
be the detoxification of several carcinogens found in
tobacco smoke. There is a wide range of electrophilic
substrates both endogenous (e.g. by-products of reactive
oxygen species activity) and exogenous (e.g. polycyclic
aromatic hydrocarbons) [12]. GSTs are dimeric proteins
that catalyze conjugation reactions between glutathione
and tobacco smoke substrates, such as aromatic hetero-
cyclic radicals and epoxides [13-15]. In addition to their
role in phase II detoxification, GSTs also modulate the
induction of other enzymes and proteins important for
cellular functions, such as DNA repair. This class of en-
zymes is therefore important for maintaining cellular
genomic integrity and, as a result, may play an important
role in cancer susceptibility [16]. The loci encoding the
GST enzymes located on at least seven chromosomes.
This multigene family divided in seven families (Alpha,
Mu, Pi, Theta, Sigma, Zeta, and Omega) with functions
ranging from detoxification to biosynthesis and cell sig-
naling. Many of the GST genes are polymorphic, there-
fore, there has been substantial interest in studying the
associations between particular allelic variants with
altered risk of a variety of diseases. Several GST poly-
morphisms have been associated with an increased or
decreased susceptibility to several diseases. Two of the
important members of the GST family, named glutathione-
s-transferase mu 1 (GSTM1) and glutathione-s-transferase
theta 1 (GSTT1) have polymorphic homozygous deletion or
null genotypes. Persons with homozygous deletions of ei-
ther the GSTM1 or the GSTT1 locus have no enzymatic
functional activity of the respective enzyme. This has been
confirmed by phenotype assays that have demonstrated
94% or greater concordance between phenotype and
genotype [3].
The GSTM1 locus has been mapped on chromosome
1p13.3, while the GSTT1 locus exists on chromosome
22q11.2. [14].
Recently in two different studies, the GSTT1 null
genotype or both the GSTT1 and GSTM1 null genotypes
interacting with current-smoking status have been
shown to be a genetic risk factor for the development of
T2DM and its cardiovascular complications [17,18].In another study to investigate the associations of
GSTM1 and GSTT1 polymorphisms with type 1 diabetes
(T1DM), the results suggest that the GSTM1 null geno-
type is associated with T1DM protection and T1DM age-
at-onset and that susceptibility to T1DM may involve
GST conjugation [19].
Regarding the complications of diabetes, it has been
shown that GSTT1 wild allele and GSTT1 wild/GSTM1
null genotype can be considered as risk factors for cardio-
vascular autonomic neuropathy in Slovak adolescents with
T1DM [20].
Recently in one study reported from the Sinai area of
Egypt on 100 T2DM patients and 100 healthy controls
matched for age, gender and origin, the proportion of
the GSTT1 and GSTM1 null genotypes was significantly
greater in diabetic patients when compared to controls.
It was reported that there was a 3.17-fold increased risk
of having T2DM in patients carrying both null polymor-
phisms compared to those with normal genotypes of
these two genes (P = 0.009) [21].
To our knowledge, there was no study regarding
GSTT1 and GSTM1 null genotypes and diabetes retin-
opathy in Iranian population. In addition there is still
debate about the results of limited number of researches
in this regard in the other parts of the world. Therefore,
in this study GSTM1 and GSTT1 null genotype as one
of the genetics factors which may be related to the dia-
betes and its complications is investigated.
Materials and methods
In this study, diabetic patients have been selected from in-
dividuals referred to Yazd Diabetes Research Center, Yazd,
Iran. Other factor such as age, sex, response to treatment
and changes in hematological indices were extracted from
patient records. Among patients with diabetes, 115 pa-
tients were selected who were 35 to 65 years old. Among
them, 58 patients had no complication of diabetes (control
group) and 57 patients had diabetes with retinopathy side
effect (case group). The criteria of retinopathy were based
on retinal examination by physician and finding neovascu-
larization (based on the WHO index). The patients were
selected by physician after examination. The research was
carried out in compliance with the Helsinki Declaration
and was approved by the Ethical Committee of Shahid
Sadoughi University of Medical Sciences, Yazd, Iran.
To examine GSTT1 and GSTM1 gene deletion in pa-
tients, a sample of 10 ml peripheral blood was taken in
tubes and DNA was extracted by salting out method. Mo-
lecular examination preformed by multiplex PCR using 3
sets of primer pairs for GSTT1, GSTM1 and β globin gene
for control. A total of 100 ng of genomic DNA was used
for PCR amplification, in 30 μL of reaction mixture that
contained 2 mM MgCl2 and 12.5 pM each of the forward
and reverse primers (Table 1). The PCR condition was one
Table 1 Primer sequences for GST multiplex PCR
Primer Sequence
GSTM1 forward 5′-GAA CTC CCT GAA AAG CTA AAG G-3′
GSTM1 reverse 5′-GTT GGG CTC AAA TAT ACG GTG G-3′
GSTT1 forward 5′-TTC CTT ACT GGT CCT CAC ATC TC-3′
GSTT1 reverse 5′-TCA CCG GAT CAT GGC CAG CA-3′
β-globin forward 5′-GAA GAG CCA AGG ACA GGT AC-3′
β-globin reverse 5′-CCA CTT CAT CCA CGT TCA CC-3′
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62°C, and 72°C for 1 min each. The PCR products were vi-
sualized using 2% agarose gel electrophoresis. DNA bands
for GSTM1, GSTT1, and β globin alleles were 219 bp, 480
bp, and 268 bp, respectively. The absence of bands for
GSTM1 or GSTT1 in the presence of β globin PCR product
indicates null genotype for each (Figure 1). Samples positive
for all three PCR products were considered ‘wild-type’. The
data were analyzed by SPSS v16 software and Chi-Square
test.
Results
From 115 diabetes patients studied, 57 had retinopathy.
Genotyping of GSTM1 revealed that among these 57 pa-
tients with retinopathy, 26 patients (45.6%) showed null
genotype while 31 patients (54.4%) were positive for
GSTM1 gene. Among 58 diabetic patients without retin-
opathy, 38 patients (65.5%) had null genotypes and 20
patients (34.5%) were positive for GSTM1 gene. The
statistical analysis of GSTM1 gene deletion in controls
(diabetes without retinopathy) (65.5%) and cases
(diabetes with retinopathy) (45.6%) group indicates a
significant relationship with df = 1, p-value = 0.04, and
χ2 = 4.646.
Regarding GSTT1 genotypes, in 57 diabetics patients
with retinopathy, 16 patients had null genotypes (28.1%)Figure 1 Gel electrophoresis showing PCR products of GSTT1, GSTM1
T+/M+; DNA from patients with positive GSTM1, GSTT1, and β-globin allele
of β-globin PCR product). T+/M-; GSTT1 null/GSTM1 positive. T-/M+; GSTT1and 41 patients were GSTT1 positive (71.9%). While
among 58 diabetic peoples without retinopathy, 10 pa-
tients had null genotypes (17.2%) and 48 patients were
GSTT1 positive (82.8%).
The statistical analysis of GSTT1 gene deletion in con-
trols (17.2%) and cases (28.1%) indicates no significant
relationship with df = 1, p-value = 0.187, and χ2 =1.94.
The statistical analysis of GSTT1 and GSTM1 inter-
action gene deletion in controls (77.59%) and cases
(22.41%) indicates a weak significant relationship with
df = 1, p-value = 0.052, and χ2 =3.34.
Discussion
Diabetes mellitus is one of the most common chronic
diseases in nearly all countries; the number of people
with diabetes is increasing due to population growth,
aging, urbanization, and increasing prevalence of obesity
and reduced physical activity.
Oxidative stress plays a major role in the pathogenesis
of T2DM. β-cells are low in antioxidant factors such as
glutathione peroxidise and catalase. Therefore, they are
particularly sensitive to oxidative stress which may not
only result from hyperglycemia associated with diabetes,
but may also have an important causal role in β-cell fail-
ure and the development of insulin resistance and
T2DM [21].
There are several complex mechanisms in human that
protect the body against environmental agents including
inappropriate dietary, UV radiation, smoking and free radi-
cals which are produced from defective oxidation. The
ability of human for metabolizing carcinogens (cancer
causing substances) varies and people who have little abil-
ity to produce detoxification substance are at high risk of
various diseases including diabetes and cancer. It seems
that glutathione is important as a carcinogen neutralizing
for free radicals [13,14]. GST modulates the effects ofand b-globin. L; Molecular weight marker. N; Negative control.
s. T-/M-; Double null genotype of GSTM1 and GSTT1 (in the presence
positive/ GSTM1 null.
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a family of phase II enzymes (molecular mass 17–28 kD)
that have major roles in catalyzing the conjugation of
glutathione to a wide variety of hydrophobic and electro-
philic substrates and carcinogens such as benzpyrene and
reactive oxygen species (ROS). Therefore, there is an in-
creasing interest in the role that polymorphisms in phase I
and phase II detoxification enzymes may play in the eti-
ology and progression of diseases. Polymorphisms reducing
or eliminating these enzyme detoxification activities could
increase a person’s susceptibility to diseases including
T2DM [21]. GSTs are multifunctional proteins that can
function as enzymes catalyzing the conjugation of glutathi-
one thiolate anion with a multitude of second substrates or
as non-covalent binding proteins for a range of hydropho-
bic ligands [13,14]. Peoples act in different ways to detoxifi-
cation, this theory can describe the risk differences for
various diseases include cancer and diabetes that cause by
exogenous and endogenous agents. GSTT1 and GSTM1
genes expressed in many form in populations and people
with null genotype have no active enzyme for detoxifica-
tion [22,23]. GSTM1 and GSTT1 null genotypes in
Caucasian populations have frequencies of approximately
40–60% and 10–20%, respectively [19,24-27]. We thus de-
termined the polymorphism frequency for each of these
enzymes in our study populations and looked for relation-
ships between them and the clinical parameters in T2DM.
There are many studies dealing with GST polymorphism
in various diseases, but only a few studies have addressed
the role of GST polymorphisms in diabetes and T2DM
complications. In the current study, we attempted to move
beyond single gene polymorphism to two-gene polymor-
phisms that may help predict the susceptibility to the inci-
dence of T2DM and their effect on T2DM complications
in Yazd province population.
The statistical analysis between GSTT1 and retinop-
athy show no significant association (p = 0.187) that con-
firms the research of others [28,29]. While the statistical
analysis between GSTM1 and retinopathy show signifi-
cant association (p = 0.04) that confirm the effect of free
radical in T2DM in other studies [30-34]. But is incon-
sistent with the only study that show GSTM1 null geno-
type might confer protection against retinopathy in
Caucasians with T2DM [35].
Finally, the statistical analysis between GSTT1 and
GSTM1 interaction in retinopathy show weak significant
association (p = 0.052). To our knowledge there is no
other research about the effect of GST genotype in side
effects of diabetes (diabetes complication), therefore
more researches with more cases is needed [28].
Conclusion
These results suggest that although the absence or dele-
tion of detoxification pathway of GSTT1 has nosignificant effect on the side effects of T2DM but
GSTM1 null genotype had significant relationship with
diabetes retinopathy, indicating the role of detoxification
of this genes in this regards.
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